Spero therapeutics announces issuance of allowance for a u.s. patent covering lead candidate tebipenem hbr

Cambridge, mass., jan. 21, 2021 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the united states patent and trademark office (uspto) has issued u.s. patent no. 10,889,587, which is directed to a crystalline formulation of tebipenem hbr, spero's oral carbapenem in development for the treatment of complicated urinary tract infection (cuti) and acute pyelonephritis (ap). in september 2020, spero announced positive top-line results from its phase 3 adapt-po clinical trial of tebipenem hbr in cuti and ap.
SPRO Ratings Summary
SPRO Quant Ranking